Form 8-K - Current report:
SEC Accession No. 0001193125-24-218131
Filing Date
2024-09-12
Accepted
2024-09-12 17:25:59
Documents
16
Period of Report
2024-09-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d881013d8k.htm   iXBRL 8-K 33080
2 EX-1.1 d881013dex11.htm EX-1.1 257274
3 EX-5.1 d881013dex51.htm EX-5.1 4936
7 GRAPHIC g881013g0912232630868.jpg GRAPHIC 2800
  Complete submission text file 0001193125-24-218131.txt   497706

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20240911.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20240911_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20240911_pre.xml EX-101.PRE 11265
19 EXTRACTED XBRL INSTANCE DOCUMENT d881013d8k_htm.xml XML 3669
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 241295836
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)